Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Payables (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Payables for 7 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Payables rose 36.77% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 36.77% year-over-year, with the annual reading at $1.6 million for FY2025, 36.77% up from the prior year.
  • Payables for Q4 2025 was $1.6 million at Fulcrum Therapeutics, down from $2.9 million in the prior quarter.
  • The five-year high for Payables was $6.0 million in Q1 2022, with the low at $1.2 million in Q4 2024.
  • Average Payables over 5 years is $3.5 million, with a median of $3.7 million recorded in 2021.
  • Peak annual rise in Payables hit 36.77% in 2025, while the deepest fall reached 60.93% in 2025.
  • Over 5 years, Payables stood at $4.8 million in 2021, then fell by 24.02% to $3.6 million in 2022, then fell by 24.22% to $2.8 million in 2023, then crashed by 57.78% to $1.2 million in 2024, then soared by 36.77% to $1.6 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $1.6 million, $2.9 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.